Creative Medical Technology Holdings (CELZ) Accumulated Expenses (2016 - 2024)
Creative Medical Technology Holdings (CELZ) posted quarterly Accumulated Expenses of $39920.0 for Q4 2024, little changed year-over-year from $39920.0 in Q1 2024, and down 6.99% quarter-over-quarter from $42920.0 in Q3 2024.
Creative Medical Technology Holdings (CELZ) Accumulated Expenses (2016 - 2024) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Accumulated Expenses for 9 consecutive years, with $39920.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Accumulated Expenses changed 0.0% year-over-year to $39920.0; the TTM figure through Dec 2024 stood at $39920.0 (changed 0.0% YoY), while the FY2024 annual figure was $39920.0, changed 0.0% from the prior year.
- Accumulated Expenses declined to $39920.0 in Q4 2024 per CELZ's latest filing, from $42920.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $200000.0 in Q3 2020 and bottomed at $24385.0 in Q4 2021.
- Historically, Accumulated Expenses has averaged $68049.8 across 5 years, with a median of $39920.0 in 2022.
- Annual changes were most pronounced in 2020 — Accumulated Expenses jumped 206.4% — and 2021, when it slumped 85.04%.
- Creative Medical Technology Holdings' Accumulated Expenses stood at $159771.0 in 2020, then slumped by 84.74% to $24385.0 in 2021, then jumped by 63.71% to $39920.0 in 2022, then changed by 0.0% to $39920.0 in 2023, then changed by 0.0% to $39920.0 in 2024.
- Business Quant data shows CELZ's Accumulated Expenses at $39920.0 in Q4 2024, $42920.0 in Q3 2024, and $39920.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 39,920.00 |
| Sep 30, 2024 | 42,920.00 |
| Jun 30, 2024 | 39,920.00 |
| Mar 31, 2024 | 39,920.00 |
| Dec 31, 2023 | 39,920.00 |
| Sep 30, 2023 | 39,920.00 |
| Jun 30, 2023 | 39,920.00 |
| Mar 31, 2023 | 39,920.00 |
| Dec 31, 2022 | 39,920.00 |
| Sep 30, 2022 | 54,920.00 |
| Jun 30, 2022 | 64,920.00 |
| Mar 31, 2022 | 29,920.00 |
| Dec 31, 2021 | 24,385.00 |
| Sep 30, 2021 | 29,920.00 |
| Jun 30, 2021 | 71,474.00 |
| Mar 31, 2021 | 67,763.00 |
| Dec 31, 2020 | 159,771.00 |
| Sep 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 158,070.00 |
| Mar 31, 2020 | 137,574.00 |